About: An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma
Creator	Kennedy, Michael Bell, John Lichty, Brian Auer, Rebecca Baxter, Katherine Daneshmand, Manijeh Tai, Lee-Hwa Tanese De Souza, Christiano Yaghini, Pasha
Source	BioRxiv
abstract	Background Although surgery provides the greatest therapeutic benefit to eligible pancreatic ductal adenocarcinoma (PDAC) patients it does not significantly improve survival for the majority of patients. Unfortunately our understanding of the therapeutic benefit of combining surgery with different treatment modalities including promising immunotherapeutics is limited by the current lack of easily adopted surgical models. The purpose of this study was to develop a surgically resectable model of PDAC in immunocompetent mice for use in preclinical investigations. Materials and Methods Surgically resectable orthotopic tumors were generated by injecting Pan02 cells into the tail of the pancreas. Fifteen days post implantation the primary tumors and tail of the pancreas were resected by laparotomy while preserving the spleen. Splenic function, tumor growth, immune phenotyping and survival were assessed following surgical resection of the primary tumor mass. Results As expected orthotopic tumor implants recapitulated many of the major histological hallmarks of PDAC including disrupted lobular structure and vascular invasion. Preservation of splenic immune cell viability and function was not associated with improved survival following surgery alone. However, pre-operative vaccination with GVAX was associated with improved survival which was not impacted by surgery. Conclusion This represents the first murine model of surgically resectable murine model of PDAC which recapitulates known pathological hallmarks of human disease in an immune competent model while allowing spleen preservation. This relatively simple and easily adopted approach provides an ideal platform to examine the efficacy of potential immunotherapy combinations for PDAC surgery patients.
has issue date	2020-03-18(xsd:dateTime)
bibo:doi	10.1101/2020.03.17.990903
has license	biorxiv
sha1sum (hex)	5eae33d6b4a413f246755b871b7254df0d463827
schema:url	https://doi.org/10.1101/2020.03.17.990903
resource representing a document's title	An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma
schema:publication	bioRxiv
resource representing a document's body	covid:5eae33d6b4a413f246755b871b7254df0d463827#body_text
is schema:about of	named entity 'survival' named entity 'efficacy' named entity 'surgery' named entity 'mice' named entity 'surgery' named entity 'Although' named entity 'therapeutic benefit' named entity 'improve' named entity 'resectable' named entity 'murine' named entity 'distal pancreatectomy' named entity 'immunotherapy' named entity 'resectable' named entity 'resectable' named entity 'CD8 +' named entity 'surgical resection' named entity 'surgical stress' named entity 'pancreas' named entity 'surgical resection' named entity 'tumor' named entity 'pancreatic tissue' named entity 'pancreas' named entity 'tumor debulking' named entity 'red pulp' named entity 'clinical evidence' named entity 'Treg' named entity 'anesthetized' named entity 'Covidien' named entity 'disease recurrence' named entity 'Flow cytometric analysis' named entity 'immunosuppressive' named entity 'tumor' named entity 'myeloid derived suppressor cells' named entity 'patient outcomes' named entity 'GVAX' named entity 'cell line' named entity 'splenocyte' named entity 'sutured' named entity 'linea alba' named entity 'preclinical models' named entity 'CD8 +' named entity 'primary tumor' named entity 'One-way analysis of variance' named entity 'cotton swab' named entity 'pancreatic adenocarcinoma' named entity 'sutured' named entity 'surgical procedures' named entity 'mice' named entity 'tumor' named entity 'muscle' named entity 'abdominal cavity' named entity 'surgical procedures' named entity 'tumor' named entity 'immunotherapy' named entity 'pancreatic cancer' named entity 'Tregs' named entity 'surgical intervention' named entity 'immune cell' named entity 'CD4' named entity 'peritoneal cavity' named entity 'GVAX' named entity 'spleen' named entity 'PBS' named entity 'resectable' named entity 'tumor' named entity 'Pancreatic tumors' named entity 'liver' named entity 'RPMI' named entity 'survival curve' named entity 'pancreas' named entity 'OHRI' named entity 'Lymphocytic' named entity 'spleen' named entity 'PDAC' named entity 'mycoplasma' named entity 'PDAC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software